Clinical Trials Logo
  1. Home
  2. ATTR Amyloidosis
  3. NCT02595983

The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant

ATTR Amyloidosis Clinical Trial

Official title:
An Open-label Study to Evaluate the Efficacy and Safety of Revusiran in Patients With Transthyretin-mediated Familial Amyloidotic Polyneuropathy With Disease Progression Post-Orthotopic Liver Transplant

Clinical Trial Summary

The purpose of this study was to evaluate the safety and effectiveness of revusiran (ALN-TTRSC) in adults with transthyretin-mediated amyloidosis (ATTR), whose disease has continued to worsen after liver transplantation. Dosing has been discontinued; patients are being followed-up for safety.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02595983
Study type Interventional
Source Alnylam Pharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date October 2015
Completion date February 6, 2017
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04561518 - ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Recruiting NCT05444920 - The Italian Transthyretin Amyloidosis Web-Network
Recruiting NCT05184088 - Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis Phase 3
Recruiting NCT06367842 - Orthopaedic Specimen Pathology and Early Diagnosis of ATTR Cardiopathy (ATTR-ORTHO)
Recruiting NCT06355934 - OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis